Literature DB >> 9668524

beta-YAC transgenic mice for studying LCR function.

K R Peterson1, P A Navas, G Stamatoyannopoulos.   

Abstract

We have developed methods to produce transgenic mice using yeast artificial chromosomes (YACs) and have applied these methods to the analysis of globin gene regulation using 248 kb beta-globin locus YACs (beta-YACs). The advantages of YAC transgenics are: 1) developmental regulation can be studied in the context of the whole locus, 2) mutations may be readily introduced into the YAC, and 3) the effect of these mutations on gene expression can be analyzed. Mice containing the wild-type beta-YAC show proper regulation of globin gene expression during development. Transgenics carrying a beta-YAC bearing a -117 A gamma mutation showed the anticipated phenotype of Greek HPFH, demonstrating that mutant beta-YACs can be used to generate mice that recreate human globin developmental mutants. Transgenic mice with YACs have also been used to examine the function of the LCR. Transgenic mice were generated with a beta-YAC containing a deletion of LCR DNAse I-hypersensitive site 3 (5'HS3). Our results suggest that: 1) the LCR contains functionally redundant elements, 2) the formation of a LCR complex does not require all of the HSs, 3) the individual HSs may modulate the interaction of the LCR with specific globin genes during development, and 4) that most of the HS activity is confined to the core region.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9668524     DOI: 10.1111/j.1749-6632.1998.tb10459.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.

Authors:  Chang Li; Nikoletta Psatha; Pavel Sova; Sucheol Gil; Hongjie Wang; Jiho Kim; Chandana Kulkarni; Cristina Valensisi; R David Hawkins; George Stamatoyannopoulos; André Lieber
Journal:  Blood       Date:  2018-05-22       Impact factor: 22.113

Review 2.  Revisiting fetal hemoglobin inducers in beta-hemoglobinopathies: a review of natural products, conventional and combinatorial therapies.

Authors:  Mandrita Mukherjee; Motiur Rahaman; Suman Kumar Ray; Praphulla Chandra Shukla; Tuphan Kanti Dolai; Nishant Chakravorty
Journal:  Mol Biol Rep       Date:  2021-11-25       Impact factor: 2.316

3.  In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice.

Authors:  Chang Li; Aphrodite Georgakopoulou; Arpit Mishra; Sucheol Gil; R David Hawkins; Evangelia Yannaki; André Lieber
Journal:  Blood Adv       Date:  2021-02-23

4.  Regulation of embryonic/fetal globin genes by nuclear hormone receptors: a novel perspective on hemoglobin switching.

Authors:  A Filipe; Q Li; S Deveaux; I Godin; P H Roméo; G Stamatoyannopoulos; V Mignotte
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

5.  Extensively self-renewing erythroblasts derived from transgenic β-yac mice is a novel model system for studying globin switching and erythroid maturation.

Authors:  Michael Getman; Samantha J England; Jeffery Malik; Kenneth Peterson; James Palis; Laurie A Steiner
Journal:  Exp Hematol       Date:  2014-04-02       Impact factor: 3.084

6.  In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.

Authors:  Chang Li; Hongjie Wang; Aphrodite Georgakopoulou; Sucheol Gil; Evangelia Yannaki; André Lieber
Journal:  Mol Ther       Date:  2020-09-05       Impact factor: 11.454

7.  An intergenic non-coding RNA promoter required for histone modifications in the human β-globin chromatin domain.

Authors:  Emmanuel Debrand; Lyubomira Chakalova; Joanne Miles; Yan-Feng Dai; Beatriz Goyenechea; Sandra Dye; Cameron S Osborne; Alice Horton; Susanna Harju-Baker; Ryan C Pink; Daniel Caley; David R F Carter; Kenneth R Peterson; Peter Fraser
Journal:  PLoS One       Date:  2019-08-14       Impact factor: 3.240

8.  Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies.

Authors:  Chang Li; Nikoletta Psatha; Hongjie Wang; Manvendra Singh; Himanshu Bhusan Samal; Wenli Zhang; Anja Ehrhardt; Zsuzsanna Izsvák; Thalia Papayannopoulou; André Lieber
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-15       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.